SCHIZOPHRENIA

This phase 1 trial tests a single injection of TV-44749, an extended-release form of olanzapine, in Chinese adults with stable schizophrenia. The study aims to check safety, tolerability, and how the drug moves through the body. Participants receive one of three doses of the inje…

This study tested a long-acting injectable (LAI) form of the drug lumateperone in 52 adults with stable schizophrenia or schizoaffective disorder. Participants received a single injection of one of several LAI formulations, along with oral capsules, to see how the drug behaves in…

This study tested the safety and tolerability of aripiprazole (Abilify) in 21 children and adolescents aged 10 to 17 with schizophrenia or mania. Participants took daily doses of 2 to 30 mg for 14 days. The main goals were to see how many could tolerate the highest dose without s…

This study tested the safety of a new drug called KarXT in 173 adults with schizophrenia. Researchers slowly increased the dose to see how well participants tolerated it and whether food affected the drug. The main goal was to track side effects, with secondary measures looking a…

This Phase 3 trial tested an investigational drug called SEP-363856 in 464 people with schizophrenia who were experiencing acute psychosis. Participants received either the drug or a placebo daily for up to 9 weeks. The study measured changes in symptoms like hallucinations and d…

This study tested a weight-loss program called CoachToFit for 257 veterans with serious mental illness (like schizophrenia or bipolar disorder) who were obese. Participants used a smartphone app, an activity tracker, and a Bluetooth scale, and worked with a peer coach. The goal w…

This study tested whether a once-monthly injection of aripiprazole can help people with schizophrenia avoid a relapse of symptoms. Over 900 adults took part, first switching to oral aripiprazole, then receiving either the long-acting shot or another treatment for up to 38 weeks. …

This study tested a long-acting injectable form of risperidone (Risperdal Consta) in 31 people with schizophrenia or schizoaffective disorder who were already receiving home-care treatment. Participants switched from their usual antipsychotic medication to receive a shot every tw…

This study tested an investigational drug called SEP-363856 in 463 people with schizophrenia who were having severe symptoms. Participants received either the drug or a placebo for 6 weeks. The main goal was to see if the drug reduced symptoms like hallucinations and emotional wi…

This study tested a special team-based program called R-FACT for people with serious mental illness who are also involved with the criminal justice system. The program provides intensive, community-based support with close coordination between mental health and justice staff. Res…

This study tested a noninvasive brain stimulation technique (transcranial random noise stimulation) to see if it could reduce cravings in 225 adults with substance use disorder plus another psychiatric condition like ADHD, bipolar disorder, or schizophrenia. The approach targeted…

This study tested whether adding memantine, a drug used for Alzheimer's, to targeted cognitive training (brain exercises) could improve thinking and daily function in people with schizophrenia or schizoaffective disorder. 62 participants took either memantine or a placebo while c…

This study looked at whether changing antipsychotic medication can better control schizophrenia symptoms in people already taking these drugs. Researchers followed 219 adults with schizophrenia or schizoaffective disorder who still had symptoms despite treatment. The main measure…

This phase 3 trial tested KarXT, a combination of two drugs, as an add-on treatment for 396 adults with schizophrenia whose symptoms were not well controlled by their current medication. Over 6 weeks, researchers measured changes in symptom severity using a standard rating scale.…

This study looked at 6 people with schizophrenia who were already taking a combination of two long-acting injectable medications: Abilify Maintena and Rexulti. Researchers tracked their symptoms and side effects over 6 months to see how well the combo worked in everyday life. The…

This study tested whether a peer-led psycho-education program (where trained patients lead group sessions) helps adults with schizophrenia improve symptoms and daily functioning over two years. 342 participants were randomly assigned to peer-led groups, professional-led groups, o…

This study tested a monthly injection of olanzapine (TV-44749) in 675 adults with schizophrenia to see if it controls symptoms better than a placebo. Participants received up to 14 injections over about a year. The goal is to offer a long-acting option that may improve treatment …

This study tested whether adding structured supportive psychotherapy to the antipsychotic drug risperidone helps improve thinking and reduce inflammation in people with schizophrenia. Forty-six male patients were split into two groups: one received risperidone plus 12 therapy ses…

This study tested whether a smartphone app designed for people with serious mental illness can help them quit smoking better than standard methods. Researchers enrolled 343 adults with conditions like bipolar disorder or schizophrenia who wanted to quit. Participants used either …

This study looked at whether taking a new once-weekly schizophrenia medication with food changes how much of the drug gets into the blood. Fifty-nine adults with stable schizophrenia took the drug once with food and once without food. The goal was to see if food affects drug leve…

This completed Phase 3 trial tested the long-term safety of the drug brexpiprazole in 295 adolescents aged 13-17 with schizophrenia. Participants took flexible daily doses of the oral tablet for up to several months. The main goal was to track side effects and see how many teens …

This trial tested a 9-month group program called Illness Management and Recovery (IMR) for 198 adults with schizophrenia or bipolar disorder. The program focused on helping participants set personal goals and manage their symptoms. Researchers measured changes in daily functionin…

This study tested a new long-acting olanzapine injection (TV-44749) against the standard oral olanzapine pill in 153 people with schizophrenia. The goal was to see if the shot delivers similar drug levels and is safe. Participants received multiple doses over 21 weeks, with resea…

This study tested whether a very low-carbohydrate ketogenic diet could improve brain network stability and thinking skills in people with schizophrenia or bipolar disorder. The diet is high in fat and low in carbs, which makes the body produce ketones that may provide extra energ…

This study looked at the long-term safety and tolerability of the drug MP-214 in 254 people with schizophrenia. Participants had already completed an earlier trial and continued taking MP-214 at flexible doses. The main goal was to track side effects over time.

This completed study tested an experimental drug called MP-214 in 512 people with schizophrenia. Participants took either a daily dose of MP-214 (3, 6, or 9 mg), an existing antipsychotic (risperidone), or a placebo for six weeks. The main goal was to see if MP-214 reduces schizo…

This study looked at a new drug called MP-214 in 38 adults with schizophrenia. The goal was to see how safe the drug is, how the body processes it, and whether it helps control symptoms. Participants took the drug for 12 weeks, and researchers monitored side effects and drug leve…

This study tested the long-term safety and effectiveness of a new daily pill called MP-214 in 125 people with chronic or elderly schizophrenia. Participants took either MP-214 or the existing drug risperidone for several weeks. The goal was to see if MP-214 is a safe and tolerabl…

This study tested three different doses of MP-214 (cariprazine) in 34 adults with schizophrenia. The goal was to check safety, how the drug moves through the body, and whether it helps control symptoms. Participants took the drug once daily for 14 days, starting low and increasin…

This study looked at the long-term safety and effectiveness of an investigational drug called MP-214 in 42 adults with schizophrenia who were already taking other antipsychotic medications. The main goal was to see how many people had side effects. The study was completed and hel…

This completed study tested Igalmi, a fast-dissolving film placed under the tongue, for managing frequent agitation in people with schizophrenia or bipolar disorder. 29 adults received the drug as needed for 7 days in a clinic. Researchers looked for signs that the drug might sto…

This study tested an experimental drug called SEP-363856 to see if it is safe to take for a long time by people with schizophrenia. 305 adults aged 18 to 65 took part for about 57 weeks. The main goal was to track any side effects or serious health problems that happened while on…

This study tested whether a mindfulness-based psychoeducation program could help people with schizophrenia improve their mindfulness and stick to their medication. Forty stable outpatients were split into two groups: one received the mindfulness program, the other got usual care.…

This study tested whether delivering coordinated specialty care (CSC) via telehealth works as well as standard in-person care for young people (ages 16–35) with early psychosis. Over 12 months, researchers tracked hospitalizations and engagement in 74 participants. The goal was t…

This study tested a new drug called KarXT in 202 Chinese adults hospitalized for schizophrenia. The goal was to see if KarXT could reduce symptoms like hallucinations and delusions better than a placebo over 5 weeks, followed by a 12-week period where everyone received the drug. …

This study tested whether adding a medication to a computer-based cognitive training program could improve thinking and daily function in people with schizophrenia or schizoaffective disorder. 68 adults completed 30 sessions of targeted cognitive training while some also received…

This study tested whether a personalized crisis plan, called the SOS Plan, could reduce hospitalizations in people with schizophrenia or schizoaffective disorder. 124 patients worked with their doctors and loved ones to create a plan outlining what to do in a crisis. The goal was…

This study looked at the safety of a new drug called SEP-363856 for people with schizophrenia who switched from their usual antipsychotic medication. 75 participants who completed a prior study were followed for up to 25 weeks. The main goal was to track any side effects or serio…

This study looked at how well a new drug, SEP-363856, works and how safe it is for people with schizophrenia who switch from their current antipsychotic medication. About 101 adults with stable schizophrenia took part over 8 weeks. The main goal was to see how many stopped the st…

This study looked at how well Risperidone ISM works for people with schizophrenia who were hospitalized after a relapse. Researchers tracked 275 patients over 56 days to see if their symptoms improved and if they could better manage daily life. The treatment is given as an inject…

This study tested whether a new paliperidone palmitate injection works the same as the standard one in 256 Chinese patients with schizophrenia. Patients received either the new or the standard injection, and researchers measured drug levels in the blood to see if they matched. Th…

This study tested a remote, personalized program to help 36 adults with schizophrenia take their medication as prescribed. Participants were randomly assigned to the program or standard care. The goal was to see if the program was practical, well-liked, and improved medication ad…

This study looked at the long-term safety of cariprazine, a medication, in 310 children and teens with schizophrenia, bipolar I disorder, or autism spectrum disorder. Over 52 weeks, researchers monitored side effects, vital signs, lab results, and movement disorders. The goal was…

This study tested a new drug called LB-102 in 359 adults with acute schizophrenia. Participants received either LB-102 or a placebo for 28 days. The goal was to see if LB-102 reduces symptoms like hallucinations and confusion better than a placebo. The trial is now complete, and …

This study tested whether peer specialists—people who have serious mental illness themselves and are trained to help others—can effectively deliver two types of therapy: Cognitive Behavioral Social Skills Training (CBSST) and Social Skills Training (SST). The goal is to help vete…

This study tested whether a higher dose of the long-acting injectable medication risperidone (Risperdal Consta) works better than the usual dose for people with schizophrenia or schizoaffective disorder who still have symptoms despite standard treatment. 160 participants received…

This study tested an experimental drug called ITI-007 in 696 adults with schizophrenia who were having a sudden worsening of symptoms. Participants received either ITI-007, a placebo, or an active comparator (risperidone) for 6 weeks. The main goal was to see if ITI-007 reduces s…

This completed study tested whether aerobic exercise or computerized cognitive stimulation could improve thinking skills in 58 adults with schizophrenia. Participants were randomly assigned to one of the two activities. The goal was to see which approach better boosts memory, att…

This study tested whether a new tablet called VHX-896 works the same as the standard drug iloperidone in 26 adults with schizophrenia or bipolar I disorder. Participants took both versions at different times to compare drug levels in the blood and check for side effects. The goal…

This Phase 3 study tested the long-term safety and effectiveness of KarXT, a combination of two drugs (xanomeline and trospium), in 566 adults with schizophrenia. Participants took KarXT twice daily for up to 52 weeks. The main goal was to see how safe and tolerable the drug is o…

This early-phase study tested a new long-acting injection of the antipsychotic drug risperidone that would only need to be given once every three months. Fifty-eight adults with stable schizophrenia received a single shot at different doses to measure how the drug moves through t…

This pilot study tested a counseling program called the Teen Marijuana Check Up, adapted for young adults (ages 13–35) who have early psychosis and use cannabis. The program uses motivational interviewing and personalized feedback over two sessions to help participants reduce or …

This study tested whether mindfulness training can prevent relapse in people with psychosis. 152 participants who were in remission were randomly assigned to either mindfulness training or standard education. Researchers tracked them for 12 months to see who had a relapse.

This pilot study tested whether adding structured supportive psychotherapy to the antipsychotic risperidone could improve cognitive function and reduce inflammation in 44 hospitalized adults with schizophrenia. Participants received either risperidone plus 12 weekly talk therapy …

This study looks at whether berberine, a natural compound, can improve cognitive problems like memory and attention in people with schizophrenia. One hundred adults aged 18-60 will take either berberine or a placebo pill for 12 weeks, in addition to their regular antipsychotic me…

This study tested whether metformin, a drug used for diabetes, can improve cognitive problems in people with schizophrenia. 120 participants took either metformin or a placebo for 24 weeks. Researchers measured changes in thinking skills and brain scans to see if metformin helps.

This study tests whether immersive virtual reality (VR) can safely help people with schizophrenia improve their thinking skills, reduce symptoms, and function better in daily life. Forty adults with schizophrenia or schizoaffective disorder will either receive VR-based cognitive …

This study tested whether low-intensity ultrasound waves aimed at a specific brain area could help reduce negative symptoms of schizophrenia, such as lack of motivation and social withdrawal. 78 adults with stable schizophrenia received either real or fake ultrasound over 20 days…

This study tested two smartphone-based digital treatments alongside standard medication for people with schizophrenia who struggle with low motivation and lack of pleasure. Over 460 adults and teens took part for 16 weeks. The goal was to see if these apps could ease these tough …

This study tested a program based on Acceptance and Commitment Therapy (ACT) for 64 caregivers of people with mental disorders. The program aimed to help caregivers build psychological resilience, manage stress better, and feel less burdened. Results showed that those who took pa…

This study tests whether a smartphone app can help reduce negative symptoms of schizophrenia, such as lack of motivation and pleasure. It includes 73 adults and older teens who already completed a previous trial with the same app. Participants use the app for 16 weeks alongside t…

This Phase 3 trial tested a sublingual film containing dexmedetomidine (BXCL501) to quickly reduce agitation in 380 adults with schizophrenia or related disorders. Participants received either the drug or a placebo film, and researchers measured changes in agitation symptoms over…

This study tested whether a 10-week virtual reality program could help people with schizophrenia stop smoking. 160 participants were split into a VR group or a no-treatment group. Researchers measured nicotine dependence, smoking behavior, and quality of life before and after the…

This study tested whether adding levetiracetam (a seizure medication) to standard antipsychotics helps people with early psychosis who still have symptoms. 65 participants took either the drug or a placebo for 12 weeks. The goal was to see if it reduces psychotic symptoms and pro…

This study looked at whether adding cognitive behavioral therapy (CBT) to standard medication (risperidone) could improve cognitive function in 42 adults with stable schizophrenia. Participants either received risperidone alone or risperidone plus 10 weekly CBT sessions. Research…

This Phase 2 trial tested whether AVP-786, a combination of two drugs, can reduce negative symptoms (like lack of emotion or motivation) in people with schizophrenia. 145 adults on stable antipsychotics received either AVP-786 or a placebo for 12 weeks. The study measured changes…

This study tested whether a 6-session educational program could help people receiving electroconvulsive therapy (ECT) feel less stigma and anxiety about their mental health treatment. Sixty adult inpatients with conditions like depression or bipolar disorder took part. Those who …

This study tested whether extra psychoeducational nursing sessions could improve quality of life, emotional well-being, and reduce anxiety in 120 adults receiving modified electroconvulsive therapy (ECT) for depression, bipolar disorder, or schizophrenia. Half the patients got th…

This study tested whether a new drug called TAK-063 can help people with schizophrenia who are having a sudden worsening of symptoms. 164 adults took either the drug or a placebo for 6 weeks. The main goal was to see if symptoms improved using a standard rating scale. The study i…

This study tested whether virtual peer support groups, co-led by a mental health clinician and a trained peer specialist, could help veterans with serious mental illness (like schizophrenia or bipolar with psychosis) feel more socially connected and less distressed. Twenty-eight …

This study tested a video game called 'Healing Town' to see if it could help people with stable schizophrenia take their medication more regularly. Twenty participants played the game, which uses stories and decisions to encourage adherence. The goal was to improve attitudes towa…

This early-stage study tested a new drug called MK-8189 (elpipodect) in 63 people with schizophrenia, including both younger and older adults, as well as healthy older volunteers. The main goal was to check the drug's safety and how the body processes it, not to cure the disease.…

This early-stage study tested the safety and how the body processes the drug brexpiprazole in 43 teenagers aged 13-17 with schizophrenia. Researchers monitored side effects and changes in vital signs over 17 days. The goal was to find a safe dose for future studies, not to measur…

This early-stage study tested a new drug called MK-8189 (elpipodect) in 53 adults with schizophrenia or schizoaffective disorder. The main goal was to see if the drug is safe and tolerable when given in increasing doses. Researchers monitored side effects and how many people stop…

This study tested a new drug called MK-8189 (elpipodect) in 499 adults having an acute episode of schizophrenia. The goal was to see if it reduces symptoms like hallucinations and delusions better than a placebo. Participants received different doses of the drug, an active compar…

This study tested a new medication called HS-10380 in 363 Chinese adults hospitalized with acute schizophrenia. The goal was to see if it reduces symptoms like hallucinations and delusions better than a placebo or an existing drug. Participants took the drug for 6 weeks, and doct…

This study tested whether luteolin, a natural supplement found in celery and chamomile tea, can improve symptoms of schizophrenia. 85 adults with schizophrenia or schizoaffective disorder took either luteolin or a placebo for 12 weeks. Researchers measured changes in overall symp…

This study tested whether adding curcumin (the active compound in turmeric) to the standard medication risperidone could improve quality of life and reduce inflammation in people with schizophrenia. Forty-four men took part and were followed for 8 weeks. The goal was to see if cu…

This study tests whether high-frequency magnetic stimulation (rTMS) can reduce auditory hallucinations in people with schizophrenia. Unlike standard low-frequency treatment that takes 15 days, this approach uses 20 Hz stimulation over just 2 days, guided by brain scans for precis…

This study tested a type of brain stimulation called theta-burst TMS to see if it can safely improve negative symptoms (like lack of motivation) and thinking problems in people with schizophrenia. 76 adults with stable schizophrenia took part in a double-blind trial where some re…

This study tested a therapy called Cognitive Behavioral Therapy for Work Success (CBTw) in 294 veterans with serious mental illness (like depression, bipolar disorder, or PTSD) who were unemployed. The goal was to help them find and keep competitive jobs, which can improve their …

This study looked at whether a 6-week mindfulness-based yoga program could improve psychological well-being and happiness in adults with schizophrenia. 91 participants from community mental health centers were randomly assigned to either the yoga program or their usual care. The …

This study tested whether two types of mild electrical brain stimulation (tDCS and tRNS) could improve memory and thinking in 36 people with schizophrenia. Participants received both types of stimulation on different days to compare effects. The goal was to see if these safe, non…

This study tested whether a non-invasive magnetic brain stimulation technique called rTMS can reduce chronic low back pain. Thirty adults with long-lasting pain received multiple sessions of rTMS over the brain's motor cortex. Researchers measured pain changes using a standard pa…

This study tested whether a gentle electrical current applied to the scalp (tDCS) can reduce symptoms of major depression, schizophrenia, OCD, generalized anxiety, and insomnia. 320 adults aged 16–65 received multiple sessions over weeks. Researchers measured symptom changes usin…

This study tested whether a smartphone app called FOCUS, along with coaching from trained clinicians, could help people with serious mental illnesses like schizophrenia and bipolar disorder. 191 participants used the app and received coaching over 12 weeks. Researchers measured c…

This study tested whether personalizing cognitive training based on a person's early auditory processing ability improves thinking and daily function in schizophrenia. 194 adults with schizophrenia or schizoaffective disorder were assigned to either a tailored program (Brain Basi…

This study tested whether adding behavioral skills training to standard employment support helps people with schizophrenia keep a job longer. 107 participants were assigned to either job support alone or job support plus skills training. The main goal was to see which group worke…

This study tested whether adding valbenazine to standard antipsychotic medication helps reduce schizophrenia symptoms in adults who did not respond well to treatment alone. Over 400 participants took either valbenazine or a placebo for 10 weeks. Researchers measured changes in sy…

This phase 3 trial tested whether iclepertin, a daily tablet, can improve learning and memory in adults with schizophrenia. Over 600 participants took either iclepertin or a placebo for 26 weeks while continuing their usual schizophrenia medication. Researchers measured changes i…

This completed Phase 4 study tested valbenazine in 59 adults with tardive dyskinesia (involuntary muscle movements) caused by psychiatric medications. Participants had schizophrenia, bipolar disorder, or major depression. Over 24 weeks, researchers measured changes in quality of …

This study tested a 12-session virtual reality program (cVR-PTP) in 37 people with schizophrenia to see if it could improve their ability to interact socially and handle daily tasks. Participants used VR headsets to practice real-life situations like waiting at a bus stop or havi…

This study tested whether a non-invasive brain stimulation technique called rTMS, guided by MRI scans, could reduce severe hallucinations in people with schizophrenia who don't respond to medication. 85 participants received either MRI-guided or standard rTMS over 5 days. The goa…

This study tested whether a non-invasive brain stimulation technique called tDCS can help people with schizophrenia whose symptoms persist despite medication. 141 adults received either real or sham tDCS over 10 sessions. The goal was to see if active stimulation leads to a meani…

This study tested whether a daily medicine called iclepertin can improve memory and thinking in adults with schizophrenia. Over 600 participants took either iclepertin or a placebo for 26 weeks, while continuing their usual schizophrenia medications. Researchers measured cognitiv…

This study tested a group therapy program called Metacognitive Training (MCT) in 18 Taiwanese adults with schizophrenia, major depression, or bipolar disorder. Over 4 weeks, participants attended 8 sessions that taught them to spot and reduce thinking biases linked to symptoms li…

This study tested two mobile health (mHealth) strategies to help people with schizophrenia manage their symptoms. 299 participants used smartphone tools to track and improve issues like depression, anxiety, and insomnia. The goal was to see if these digital tools could make a rea…

This study tested whether a 4-week virtual reality (VR) training program could improve thinking skills in 62 people with depression, bipolar disorder, or psychotic disorders like schizophrenia. Participants practiced daily-life tasks in VR, such as cooking and shopping, guided by…

This study tested the safety and tolerability of lumateperone, an antipsychotic drug, in 26 adolescents aged 13 to 17 with schizophrenia or schizoaffective disorder. Participants took either 28 mg or 42 mg of lumateperone by mouth. Researchers measured how the drug moves through …

This study tested a medicine called iclepertin to see if it improves memory and thinking in adults with schizophrenia. About 620 participants took either iclepertin or a placebo daily for 26 weeks, while continuing their usual schizophrenia medications. Researchers measured chang…

This study tested two doses of a new drug called emraclidine (CVL-231) in 391 adults with schizophrenia who were having a sudden worsening of psychotic symptoms. Participants took the drug or a placebo daily for 6 weeks. The main goal was to see if the drug reduced symptoms like …

This study tested whether a new drug called ITI-007 can reduce symptoms of schizophrenia during an acute psychotic episode. 335 adults with schizophrenia were randomly assigned to receive ITI-007, a placebo, or an active control for 28 days. The main goal was to measure changes i…

This study tested a group therapy called Social Cognition Interaction Training (SCIT) to help people with schizophrenia better understand social cues. About 51 adults with schizophrenia or schizoaffective disorder took part, either receiving SCIT or being placed on a waitlist. Th…

This study tested a group-based cognitive training program for people with schizophrenia who have had the condition for less than 10 years. The program teaches practical strategies to work around memory, attention, and planning problems. Researchers compared the costs and daily f…

This study tested whether having people with schizophrenia watch a video of themselves recorded during a psychotic episode could improve their awareness of their illness. Sixty patients were randomly assigned to either watch the video or not. The goal was to see if this simple to…

This study tested whether taking part in art activities (like painting, music, or dance) can improve mental well-being. 382 people with mental health issues such as anxiety, depression, or emotional disorders were randomly assigned to either an art program or a waitlist. The stud…

This study tested whether a new drug called ITI-007 can reduce symptoms of schizophrenia better than a placebo. About 450 adults with schizophrenia who were having a sudden worsening of symptoms took part. The main goal was to see if their symptoms improved after 28 days of treat…

This study tested a non-invasive light therapy called photoneuromodulation in 30 adults with schizophrenia whose negative symptoms (like lack of motivation or social withdrawal) did not improve with standard treatments. Participants received either real or sham light sessions, th…

This study looked at whether cognitive behavioral therapy (CBT) can help veterans with serious mental illnesses like schizophrenia or bipolar disorder manage chronic pain. 47 veterans took part in a 12-session CBT program designed for chronic pain. The goal was to see if the ther…

This Phase 2 trial tested two doses of emraclidine (10 mg and 30 mg daily) against a placebo in 385 people with schizophrenia who were having a sudden worsening of psychotic symptoms. The study lasted 6 weeks and measured symptom changes using a standard rating scale. The goal wa…

This study tested an investigational medication called BXCL501 (dexmedetomidine) given as a film under the tongue for episodes of agitation in people with schizophrenia, schizoaffective disorder, or bipolar disorder. The trial included 452 adults aged 18-75 and compared the drug …

This study tested whether virtual reality training or physical activity could improve physical function, thinking, and quality of life in 45 adults with schizophrenia. Participants did either VR gaming or structured exercise for 12 weeks. Researchers measured balance, walking abi…

This study tested a new drug called CPL500036 in 189 people having a sudden worsening of schizophrenia symptoms. Participants took either a low dose, high dose, or placebo for 28 days. The main goal was to see if the drug reduces symptoms like hallucinations and delusions better …

This study tested whether computer-based visual exercises can help people with schizophrenia who have trouble with contrast sensitivity and organizing visual information. Researchers compared several training programs, including one called UltimEyes, in 79 participants. The goal …

This study tested whether a structured breathing therapy program could reduce sleep problems and fatigue in people with schizophrenia. Sixty-eight patients took part, with one group receiving eight sessions of breathing therapy while the other group received no extra care. Resear…

This completed study from the National Institute of Mental Health looked at nearly 5,000 people with schizophrenia or related disorders, along with their siblings. The goal was to find genes linked to the illness and see how they affect brain function. This research helps scienti…

This study used PET scans to measure blood flow in the frontal lobe while participants performed thinking tasks. It included healthy volunteers and people with schizophrenia or Parkinson's disease. The goal was to understand how the frontal lobe works during cognitive activities …

This study looked at how dopamine receptors in the brain work in people with schizophrenia compared to healthy volunteers. Researchers used special PET and MRI scans to measure two types of dopamine receptors. The goal was to better understand what causes schizophrenia, which cou…

This study looked at how schizophrenia affects physical activity, balance, muscle strength, and thinking skills. Researchers measured these abilities in 35 adults diagnosed with schizophrenia. The goal was to better understand the challenges patients face, which could help improv…

This study investigates how a medication called lorazepam, which boosts the calming brain chemical GABA, changes emotional brain activity in people with psychosis. Participants aged 16–60 with conditions like schizophrenia or bipolar disorder, along with healthy volunteers, will …

This study looked at how people with schizophrenia process sounds and remember where information comes from. Researchers tested 50 participants (patients and healthy controls) using computer tasks. The goal was to understand if trouble telling sounds apart relates to difficulty d…

This pilot study tested a community-based intervention for people with psychosis in Malawi, Nigeria, Sierra Leone, and Zimbabwe. The program includes peer support from someone who has experienced psychosis, case management, and help with daily activities like finding work or soci…

This study used PET scans to look at dopamine and blood flow in the brains of 502 people, including healthy volunteers and those with Parkinson's disease or schizophrenia. The goal was to understand how these conditions affect brain function and to compare inherited versus non-in…

This study used advanced brain imaging (MRI and MEG) to look for differences in brain structure, chemistry, and activity between people with schizophrenia and healthy volunteers. Over 3,200 adults took part. The goal was to better understand the brain changes linked to schizophre…

This completed study looked at how the brains of people with schizophrenia work when they are not taking antipsychotic medication. The goal was to tell apart the effects of the illness itself from the effects of the drugs. 648 participants stayed in a hospital and underwent brain…

This completed study looked at how rising temperatures affect people with chronic conditions like heart disease, diabetes, and depression. Researchers in Germany and Italy surveyed 176 patients to see what symptoms they experienced during heat and what protective steps they took.…

This study tested a 4-session education program for people with early schizophrenia. The goal was to see if it helps patients feel more connected to their therapist, which is important for ongoing care. 21 hospitalized patients took part, and researchers measured changes in the p…

This study looked at how people with schizophrenia perceive familiarity when looking at faces. Researchers showed 30 participants blended images of familiar and unfamiliar faces and asked them to press a button when they felt a sense of familiarity. The goal was to understand how…

This study tested a smartphone app called A4i designed to help people with schizophrenia manage their illness and stay connected with their care providers. 91 adults with schizophrenia or related disorders used the app for 6 months. The goal was to see if the app was practical an…

This early-stage trial tested the safety and tolerability of multiple doses of TAK-063 in 77 participants, including people with stable schizophrenia and healthy Japanese volunteers. Researchers monitored side effects, lab results, and vital signs over 7 days. The study does not …

This early-stage study tested a new drug called MK-8189 in 55 people, including healthy volunteers and those with schizophrenia. The main goal was to see if the drug is safe and how it behaves in the body. Researchers measured drug levels and side effects, but this study did not …

This study checked whether a high dose of the experimental drug MK-8189 (elpipodect) affects heart rhythm in people with schizophrenia. 107 participants received the drug, a placebo, and an active control in a crossover design. The main goal was to see if the drug causes a danger…

This early-stage study tested a new oral drug, SEP-380135, in 43 adults with schizophrenia or major depression (including bipolar disorder). The main goal was to check its safety and how the body processes it. Participants took multiple doses and were monitored for side effects, …

This study followed 51 people with schizophrenia who were already stable on long-acting injectable antipsychotics. Over 48 weeks, researchers checked every 12 weeks whether patients stayed well or had a relapse. The goal was to see how often symptoms return when medication adhere…

This study looked at how well patients, their family members, and doctors agree when rating agitation episodes in people with bipolar disorder or schizophrenia. Thirty-three adults received a treatment called BXCL501, and researchers compared different questionnaires to see which…

This completed study followed 509 children aged 3 to 18 who were taking risperidone or aripiprazole for conditions like schizophrenia or bipolar disorder. Researchers measured weight changes over up to 50 months to understand long-term risks. The goal was to provide better safety…

This completed observational study followed 168 pregnant or breastfeeding women with schizophrenia, psychosis, or mania who were already taking long-acting injectable antipsychotics. Researchers measured drug levels in the mother's blood, breastmilk, and the baby's blood to under…

This study tested how low (1 Hz) and high (20 Hz) frequency repetitive transcranial magnetic stimulation (rTMS) changes brain activity in 30 healthy adults. Participants received both types of stimulation in separate sessions, and their brain waves were measured before and after.…

This completed study looked at how teenagers with autism or schizophrenia understand emotions, metaphors, and social situations compared to healthy teens. Researchers tested 60 participants using facial emotion recognition and other tasks. The goal was to find out if social diffi…

This study tested whether sending text message reminders and support to young people with psychosis after an emergency room visit helps them attend their first early psychosis appointment. 186 participants were enrolled. The goal was to see if a low-cost, youth-friendly approach …

This study tested a program called NAVIGATE, which provides coordinated care for youth and young adults (ages 14-35) who have had a first episode of psychosis. The goal was to see if NAVIGATE helps improve recovery, reduce hospital stays, and lower healthcare costs compared to st…

This study tested a new mobile app called iTEST that helps people with schizophrenia or schizoaffective disorder improve how accurately they judge their own performance on memory and emotion recognition tasks. 69 adults completed daily exercises on a smartphone for 16 weeks, gues…

This study tested whether a scale that measures personal and social performance can predict symptom improvement in people with schizophrenia. Over 700 participants taking paliperidone were followed for 12 weeks. Results showed that those with better social functioning scores were…

This study tested a new digital tool called CBTpro that uses artificial intelligence to help therapists improve their skills in cognitive behavioral therapy for psychosis (CBTp). Over 600 participants, including therapists and their clients with conditions like schizophrenia or b…

This study tested a program called CRAFT-EP, which helps families support a relative with early psychosis and substance use (like alcohol or cannabis). The program was delivered entirely through video calls. Researchers measured family members' depression and anxiety to see if th…

This study tested whether a brain wave measurement called mismatch negativity (MMN) can help match veterans with mental illness to the most effective cognitive training program. 100 veterans with conditions like schizophrenia, PTSD, or mood disorders participated. The goal was to…

This study looked at how a supplement called N-acetylcysteine (NAC) affects brain chemicals and thinking in 88 adults with schizophrenia or related disorders. Participants took tryptophan to raise a brain chemical called kynurenic acid, then had cognitive tests and brain scans. T…

This study looked at the dental health of 110 adults with schizophrenia in Côte d'Or, France. Participants received a mouth exam, a blood test for vitamin C levels, and answered a 30-minute questionnaire about their dental care and eating habits. The goal was to understand their …

This pilot study tested an automated phone system called 'My Coach Connect' for people with chronic mental illness. Participants called in twice a week to answer questions about how they were doing. The goal was to see if the system was easy to use and helpful for both patients a…

This study tested a new questionnaire to measure how people with schizophrenia perceive their own oral health. Researchers enrolled 59 patients who completed surveys about their oral health and quality of life. The goal is to create a reliable tool to guide better dental preventi…

This study looked at how caregivers' beliefs and attitudes might help or get in the way of teaching patients with schizophrenia to manage their own health. Researchers interviewed 21 medical and paramedical staff in France, both those who had given such education and those who ha…

This study tested a program that combines education about schizophrenia with motivational interviewing to see if it helps patients learn more about their condition and feel more hopeful. 44 adults with schizophrenia took part, with half receiving the program and half getting usua…

This completed phase 1 trial enrolled 12 healthy adults to see how a single dose of the experimental schizophrenia drug SEP-380135 interacts with quinidine, a medicine that blocks a key liver enzyme. Researchers measured drug levels in the blood and monitored safety. The goal is …

This study looked at how a non-invasive brain stimulation technique called TMS affects brain activity in people with schizophrenia. Ten participants received both real and fake TMS in separate sessions. Researchers measured brain connections and electrical signals before and afte…

This study looked at how young people (ages 15-35) with a parent or sibling who has schizophrenia process social cues like facial expressions. Researchers used brain scans and emotion recognition tests to understand these abilities. They also tested whether a computer-based train…

This study tested a program called Collaborative Decision Skills Training (CDST) to help veterans with serious mental illness (like schizophrenia or major depression with psychosis) work more closely with their doctors in making treatment decisions. The program involved eight wee…

This study looked at whether a memory technique called 'retrieval practice' works in people with schizophrenia. Participants studied word pairs and were later tested or re-studied them. The goal was to see if testing improves recall more than re-studying. 40 people took part, inc…

This study looked at how people with schizophrenia organize memories of events. Participants took a 1-hour walk in Strasbourg while wearing an automatic camera. Later, they were asked to put photos from the walk in order and identify where events started and ended. The goal was t…

This study looked at how people aged 15-45 with early psychosis process information about their surroundings, called state representation. Researchers tested two types of cognitive training and measured changes in thinking and brain activity using computer tasks and scans. The go…

This study looked at how the brain creates the feeling of being in control of our own actions. Researchers compared healthy volunteers with people who have schizophrenia or bipolar disorder, especially those who feel their actions are controlled by an outside force. The goal was …

This study tested two types of brain stimulation (TMS) in 90 people who smoke, half with schizophrenia and half without. The goal was to see if TMS could change brain connections and reduce nicotine cravings. Participants completed thinking tasks and reported their cravings befor…

This study looked at whether cannabis or a similar drug (dronabinol) can improve brain reward function in people with schizophrenia who also use cannabis. 263 participants took part to see if these substances help regulate brain circuits linked to motivation and pleasure. The goa…

This study tested whether a generic version of the schizophrenia drug brexpiprazole works the same as the brand-name drug (Rxulti). Thirty-six healthy adults took a single dose of each version, and researchers measured drug levels in their blood. The goal was to see if the generi…

This completed study compared two schizophrenia medications, aripiprazole and risperidone, in 60 patients to see how they affect mitochondria—the energy factories inside cells. Researchers measured changes in mitochondrial activity and related blood markers over 12 weeks. The goa…

This study tested whether a smartphone app could help veterans with serious mental illnesses like schizophrenia and bipolar disorder track their own symptoms. 87 veterans used the app to monitor their activity, sleep, and social interactions. The goal was to see if this data coul…

This study looked at how people aged 18-30 with early psychosis process information about their surroundings, compared to those without a psychiatric diagnosis. Participants completed computer-based tasks and cognitive training. The goal was to better understand thinking patterns…

This completed study tested whether targeted brain stimulation (TMS) could affect attention and nicotine cravings in 15 people with schizophrenia or schizoaffective disorder who smoke. Researchers applied different types of TMS to a brain network linked to attention and measured …

This completed study looked at how people aged 15-45 with early psychosis process information from their surroundings, compared to healthy young adults. Participants completed computer tasks and had their brain activity measured using EEG and MRI scans. The goal was to better und…

This study tested whether digital tools like smartphone apps and wearable rings can help track mental health symptoms in daily life. Over 300 adults with conditions like depression, bipolar disorder, or anxiety used an app and a smart ring for several weeks. The goal was to see i…